Plus Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Plus Therapeutics, Inc. reported its financial results for the first quarter of 2026, focusing on its CNSide commercial scale-up and the pivotal trial readiness for REYOBIQ, a novel injectable radiotherapy aimed at treating CNS tumors. The company has expanded payer coverage for CNSide to approximately 81 million lives and received FDA Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas. Plus Therapeutics is committed to advancing its products through continued clinical trials and partnerships.
HOUSTON, May 15, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today announces financial results for the first quarter ended March 31, 2026 and provides an overview of recent and upcoming business highlights.